Study protocol for identification of patients with risk of cognitive impairment in advanced pharmaceutical care in a community pharmacy
Bibliographic Data
| ID | 22089992 |
|---|---|
| Authors | Zuzana Macekova (University of Veterinary Medicine in Košice), Michaela Krivosova (0000-0002-5876-1473, Comenius University Bratislava), Nikola Hudakova (0000-0002-0941-2357, University of Veterinary Medicine in Košice), Jozef Dragašek (0000-0003-2938-6675, University of Pavol Jozef Šafárik), Michal Hajdúk (0000-0002-7073-7564, Comenius University Bratislava), Viera Zufkova (Comenius University Bratislava), Ján Klimas (0000-0002-5179-0052, Comenius University Bratislava, corresponding author), Miroslava Snopkova (0000-0001-8347-599X, Comenius University Bratislava) |
| Year | 2025 |
| Volume | 13 |
| Pages | 1606381-1606381 |
| Publication date | 2025-08-12 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2025.1606381 |
| PMID | 40873979 |
| OpenAlex | W4413194044 |
| Language | EN |
| References cited | 40 |
Introduction: Cognitive impairment (CI) is a growing public health problem. Our study is based on the fact that cognitive assessment in community pharmacy focused on early identification of undiagnosed CI has received limited attention. As pharmacists are the most accessible health professionals due to the availability of community pharmacies to the public, they have the potential to bring improvement in this area. Early identification of at-risk patients with CI by performing cognitive testing within advanced pharmaceutical care may improve the availability of targeted physician-indicated treatment. Methods and analysis: The study is a multicentric study that will include cognitive screening within pharmaceutical care. We will use the Slovak version of the short form of the Montreal Cognitive Assessment (s-MoCA) test. Study participants will be at-risk patients undergoing cognitive screening in community pharmacies. Secondarily, we will evaluate the risk factors related to CI, such as at-risk medication use and modifiable dementia risk factors (e.g., cardiovascular and mental comorbidities, aging, and lifestyle habits). Ethics and dissemination: This study was approved by the Ethics Committee of the Faculty of Pharmacy, Comenius University Bratislava (Ethics Committee Statement 01/2024). All procedures follow the relevant guidelines and regulations and the Declaration of Helsinki
Alternative medicine · Cognition · Cognitive impairment · Declaration · Dementia · Disease · Family medicine · Health care · Informed consent · Montreal Cognitive Assessment · Pharmaceutical care · Psychiatry · Public health · Cancer-related cognitive impairment studies · Dementia and Cognitive Impairment Research · Medicine · Nursing · Pharmaceutical Practices and Patient Outcomes · Gerontology · Pharmacy
Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation
Older Adults' Reasons for Using Technology while Aging in Place
Dementia prevention, intervention, and care
Dementia prevention, intervention, and care
“Mini-mental state”
The Montreal Cognitive Assessment, MoCA
Social support, positive caregiving experience, and caregiver burden in informal caregivers of older adults with dementia
| Highly cited | No |
|---|